Business · Companies · 9 hrs ago
Reig Jofre profit falls 46% as sales remain almost flat
Reig Jofre earned €1 million from January to September 2026, 46% less than in the same period a year earlier.
Its revenue was nearly unchanged, falling 0.5% to €241 million.
A fire in France disrupted supplies of its Forté Pharma products in France and Belgium for six months.
Work to upgrade its Barcelona plant reduced production of injectable and freeze-dried medicines, while the end of a European project also affected the figures.
Sales rose 10% in dermatology and bone and joint health, but fell 1% in hospital products and 12% in nutritional supplements.
Reig Jofre expects gradual growth from late 2026, with stronger growth in 2027 as production and sales recover.
Reig Jofre reported net profit of €1 million for January to September 2026, down 46% from the same period a year earlier.
Revenue fell 0.5% to €241 million.
The company said results were affected by a fire in France, work to improve its Barcelona plant and the end of the Emintech project.
Ebitda fell 21% to €19 million.
Reig Jofre expects gradual growth from late 2026, with stronger momentum in 2027.
- Who
- Reig Jofre, a pharmaceutical company.
- What
- Net profit fell 46% to €1 million, while revenue declined 0.5% to €241 million.
- When
- January to September 2026.
- Where
- The company’s operations were affected in France, Belgium, Toledo and Sant Joan Despí in Barcelona.
- Why
- A fire disrupted Forté Pharma supplies, improvement work reduced production at the Barcelona plant, and the Emintech project ended.
This story does not have two clearly opposing sides.
Reig Jofre earned €1 million and recorded revenue of €241 million.
A fire in France affected Forté Pharma supply in France and Belgium.
The company expects gradual growth after restarting its Toledo factory, recovering Forté Pharma’s commercial activity and receiving authorization to normalize production in Sant Joan.
- Net profit
- €1 million, down 46%
- Revenue
- €241 million, down 0.5%
- Ebitda
- €19 million, down 21%
- Forté Pharma sales
- Nutrition supplements division sales fell 12%
- Dermatology and osteoarticular health
- Sales rose 10%
What people are saying
2026 is proving to be a demanding year, marked by significant operational challenges and a decisive investment effort for our future.